Display Settings:

Format

Send to:

Choose Destination
    Trends Neurosci. 2004 Mar;27(3):155-60.

    Equivocal roles of tissue-type plasminogen activator in stroke-induced injury.

    Source

    Université de Caen, CNRS UMR 6551, Centre Cyceron, IFR 47, Boulevard H. Becquerel, BP 5229, 14074 CAEN Cedex, France.

    Abstract

    Stroke represents a major health problem in the ever-ageing population of industrialized nations. Each year, over three million people in the USA alone suffer from this affliction. Stroke, which results from the obstruction of an intra- or extra-cerebral artery, induces irreversible neuronal damage. The clot-busting drug tissue-type plasminogen activator (tPA) is the only FDA-approved therapy for acute stroke. Although tPA has been successfully used to treat myocardial infarction due to clot formation, its use in the treatment of occlusive cerebrovascular diseases remains controversial. Indeed, tPA is clearly beneficial as a thrombolytic agent. However, increasing evidence suggests that tPA could have direct and deleterious effects on neurons and glial cells.

    PMID:
    15036881
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk